Lutetium (177Lu) oxodotreotide - Wikipedia
WEBLutetium (177Lu) oxodotreotide is a radioactive drug used to treat cancers that express somatostatin receptors. It is a chelated complex of lutetium with dotatate, a somatostatin analog, and has the brand name Lutathera.
Lutetium - Wikipedia
WEBThe isotope 177 Lu emits low-energy beta particles and gamma rays and has a half-life around 7 days, positive characteristics for commercial applications, especially in therapeutic nuclear medicine. [42]
Lutetium (177Lu) vipivotide tetraxetan - Wikipedia
WEBLutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto)
WEBLearn about lutetium-177 PSMA therapy (Pluvicto), a new radiation treatment that targets prostate cancer cells with PSMA. Find out who is eligible, how it works, and what are the benefits and side effects.
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate ...
WEBJun 23, 2021 · Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
FDA approves Pluvicto for metastatic castration-resistant prostate ...
WEBOn March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the...
PLUVICTO® | Lutetium Lu 177 vipivotide tetraxetan
WEBWhat is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration …
Systemic Therapy Update on 177Lutetium-PSMA-617 for …
WEBJan 24, 2023 · ASCO recently published a rapid recommendation systemic therapy update on lutetium-177 (177 Lu)-PSMA-617 (vipivotide tetraxetan) for metastatic castration-resistant prostate cancer. 1 This therapy delivers targeted beta-particle radiation to prostate-specific membrane antigen (PSMA)–expressing tumor cells leading to DNA damage and …
Lutetium-177 shows significant rPFS benefit for ... - Mayo Clinic
WEBJan 20, 2024 · A phase 3 trial shows that lutetium-177 (177 Lu)-PSMA-617, a radiopharmaceutical, delays radiographic progression in patients with PSMA-positive mCRPC who have not received taxane chemotherapy. The treatment is well tolerated and may offer an alternative to chemotherapy for some patients.
Lu-177 PSMA vs Comparator Treatments and Survival in …
WEBUS Food and Drug Administration. FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen …